Alzamend Neuro Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Alzamend Neuro Inc (ALZN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Alzamend Neuro Inc vs Its Competitors
- Scale: Alzamend Neuro Inc ranks #405 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Alzamend Neuro Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Alzamend Neuro Inc | - | - | - | Yes |
| Competitors combined (21) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ALZN Stock Performance relative to its Competitors
ALZN Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 282.9% | Outperformed |
| 2 | Alto Neuroscience Inc | 282.9% | Outperformed |
| 3 | Compass Pathways Plc | 282.9% | Outperformed |
| 4 | Biogen Inc | 282.9% | Outperformed |
| 5 | Eli Lilly And Company | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Alzamend Neuro Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Alzamend Neuro Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Alzamend Neuro Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Alzamend Neuro Inc |
5.98 | - |
 Eli Lilly And Company |
1,266,984.14 | 86,462.00 |
 Johnson and Johnson |
690,566.66 | 99,335.00 |
 Novartis Ag |
318,410.85 | 56,674.00 |
 Pfizer Inc |
167,831.43 | 63,625.00 |
 Bristol myers Squibb Company |
126,875.40 | 50,033.00 |
| SUBTOTAL | 2,744,842.90 | 417,365.83 |
Sign in to see all competitors of Alzamend Neuro Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Alzamend Neuro Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Alzamend Neuro Inc's Competitors Named by the Company
Competitive relationships identified from Alzamend Neuro Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Biogen Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Pfizer Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Alzamend Neuro Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Alzamend Neuro Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Biogen Inc | Reportable 100.00 % |
| Indivior Pharmaceuticals Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Alzamend Neuro Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Alzamend Neuro Inc | 6 | - | -1,516,117 |
| Eli Lilly And Company | 1,266,984 | 1,729,240 | 551,594 |
| Johnson and Johnson | 690,567 | 705,504 | 114,311 |
| Novartis Ag | 318,411 | 752,973 | 185,566 |
| Pfizer Inc | 167,831 | 848,333 | 54,160 |
| Bristol myers Squibb Company | 126,875 | 1,539,477 | 284,338 |
| PEERS TOTAL | 2,744,837 | 1,082,288 | 203,237 |
Sign in to see all peers for Alzamend Neuro Inc .
Alzamend Neuro Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Pfizer Inc | United States 63.93 % |
| Bristol myers Squibb Company | United States 69.43 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Alzamend Neuro Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Alzamend Neuro Inc's industry classification, broader than the peer set above. Market cap in millions of $.Alzamend Neuro Inc ranks #405 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 983, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,267,410 | 23.79 % |
| 2 | Johnson and Johnson | 688,169 | 12.92 % |
| 3 | Abbvie Inc | 519,284 | 9.75 % |
| 4 | Merck and Co Inc | 364,892 | 6.85 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 405 | Alzamend Neuro Inc | 6 | 0.00 % |
Market cap and industry share for the rest of Alzamend Neuro Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-10.
Alzamend Neuro Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 400 | Theriva Biologics inc | 8 | -40.79 % |
| 401 | Actuate Therapeutics Inc | 8 | -94.82 % |
| 402 | Gt Biopharma Inc | 7 | 599.24 % |
| 403 | Inmed Pharmaceuticals Inc | 7 | - |
| 404 | Tempest Therapeutics Inc | 1,234 | 12.3% |
| 405 | Alzamend Neuro Inc | 6 | -43.91 % |
| 406 | Fibrobiologics Inc | 1,234 | 12.3% |
| 407 | Enveric Biosciences Inc | 1,234 | 12.3% |
| 408 | Exicure Inc | 1,234 | 12.3% |
| 409 | Integrated Biopharma Inc | 1,234 | 12.3% |
| 410 | Shuttle Pharmaceuticals Holdings Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Alzamend Neuro Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-10. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Alzamend Neuro Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.4x | - |
| EV / EBITDA | - | 15.3x | - |
| P/B | 1.3x | 4.2x | -2.9x |
| Return on Equity | -244.56 % | industry aggregate | -260.91 % |
| Return on Invested Capital | -119.61 % | -9.78 % (avg) | -109.83 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Alzamend Neuro Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | - |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | - | -381.36 % | - | -78.29 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Alzamend Neuro Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Alzamend Neuro Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Alzamend Neuro Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 983 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Alzamend Neuro Inc's dedicated Suppliers and Customers pages, not here.
Alzamend Neuro Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Alzamend Neuro Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Alzamend Neuro Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 260.9 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (40.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Alzamend Neuro Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Alzamend Neuro Inc | 3.07 | 3.48 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
Sign in to see all peers for Alzamend Neuro Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Alzamend Neuro Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Alzamend Neuro Inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| PEERS TOTAL | +11.3 % | +0.0 % |
Sign in to see all peers for Alzamend Neuro Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Alzamend Neuro Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Alzamend Neuro Inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
Sign in to see all peers for Alzamend Neuro Inc .
Alzamend Neuro Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Alzamend Neuro Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
Sign in to see all peers for Alzamend Neuro Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Alzamend Neuro Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Alzamend Neuro Inc | - | - |
| Eli Lilly And Company | 46.04 | 14.65 |
| Johnson and Johnson | 42.67 | 6.95 |
| Novartis Ag | 22.77 | 5.62 |
| Pfizer Inc | 41.53 | 2.64 |
| Bristol myers Squibb Company | 13.70 | 2.54 |
| PEERS AVERAGE | 35.03 | 6.58 |
Sign in to see all peers for Alzamend Neuro Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.